DIRS.INFO The most relevant business & tech news

☆ Doctors say RFK Jr.’s anti-Ozempic stance perpetuates stigma and misrepresents evidence
▼ + stars: | 2024-11-17 | by ( Meg Tirrell | ) edition.cnn.com time to read: +9 min

Sanjay Gupta Reports: Is Ozempic Right For You?” at 8 p.m. Sunday, November 17, on CNN. Even as they agree that it’s important to address growing rates of diabetes and obesity, doctors in that field say Kennedy’s plans miss the mark. Not everyone with obesity will want the drugs, and for some, they may have strong side effects such as nausea. Doctors who treat people with obesity suggest that fixing the food system shouldn’t be mutually exclusive with using weight-loss medications, when appropriate. “But a lot of his thinking is like ‘A plus B plus C plus miracle, and you’ve got an answer.’”

Persons: Sanjay Gupta, Robert F, Kennedy Jr, Donald Trump’s, —, ” Kennedy, Greg Gutfeld, Kennedy, European Union “, Ozempic, ideation, Michael Osterholm, ” Osterholm, “, Trump, he’s, Kennedy’s, Josh Green, that’s, Kennedy —, ”, Jody Dushay, Dr, Angela Fitch, “ We’ve, ” Fitch, we’ve, ‘, ” Dr, Daniel Drucker, ” Drucker, don’t, they’re, Fitch, Doctors, Elon Musk, who’s, ” Musk, It’s, he’d, you’ve, ’ Organizations: CNN, US Department of Health, Human Services, Fox News, Novo Nordisk, Danish Medicines Agency, European Union, US Food and Drug Administration, Infectious Disease, University of Minnesota, FDA, US Centers for Disease Control, National Institutes of Health, Centers, Medicare, Services, HHS, Hawaii Gov, Environmental Protection Agency, BMI, Harvard Medical School, Beth Israel Deaconess Medical, Fox, CNN Health, NPR, Trump Locations: Denmark, America, Hawaii, Samoa

☆ What the results of Wegovy’s longest clinical trial yet show about weight loss, side effects and heart protection
▼ + stars: | 2024-05-13 | by ( Meg Tirrell | ) edition.cnn.com time to read: +10 min

CNN —New analyses of the longest clinical trial yet of the weight-loss drug Wegovy are shedding light on how quickly it helps people lose weight, how long they sustain that weight loss and how safe the medicine is over four years of use. A previous clinical trial showed even greater average weight loss for Wegovy: about 15% on average over 68 weeks, compared with 2.4% for people who got a placebo. It was sustained for up to four yearsThe results showed that the 10% average weight loss for people using Wegovy was sustained for up to 208 weeks, or four years. Patients stayed on the medicine while they sustained the weight loss. Almost 23% of people on Wegovy lost at least 15% of their body weight, compared with 1.7% on a placebo.

Persons: Wegovy, –, ”, Harlan Krumholz, Dr, Donna Ryan, Eli Lilly, wasn’t, they’d, Daniel Drucker, it’s, John Deanfield, Krumholz, Drucker, GLP, Sanjay Gupta Organizations: CNN, Yale University, Yale New Haven Hospital, drugmaker, Nordisk, Novo Nordisk, European, Obesity, Nature, Pennington Biomedical Research, University of Toronto, University College London, CNN Health Locations: Baton Rouge , Louisiana, Novo

☆ ‘Ozempic babies’: What the science says on whether GLP-1s lead to surprise pregnancies, and their safety if they do
▼ + stars: | 2024-05-08 | by ( Mira Cheng | Meg Tirrell | ) edition.cnn.com time to read: +12 min

“I was depressed, severely depressed for that whole time.”Five months earlier, in October 2022, Bentley had started taking Mounjaro for weight loss. Ozempic uses the active ingredient semaglutide, and Wegovy is the version approved for weight loss. Mounjaro uses tirzepatide, which also targets a second hormone called GIP, and Zepbound is its brand name for weight loss. Safety in pregnancyEven as GLP-1 medicines may increase fertility, little is known about their safety during pregnancy. “It’s kind of like heart failure or sleep apnea,” he said, referring to conditions for which GLP-1 drugs have recently shown positive results.

Persons: CNN — Catera Bentley, Bentley, ”, “, ” Bentley, she’d, —, ‘, ’ Bentley, Jody Dushay, Dushay, Catera Bentley, Ivy, Daniel Drucker, ” Drucker, they’re, Drucker, Eli Lilly, ” Dushay, haven’t, That’s, Anuja Dokras, Dokras, Melanie Cree, Cree, PCOS, aren’t, Eli Lilly’s, Daniel Skovronsky, ” Skovronsky, Dr, Sanjay Gupta, it’s, Mounjaro Organizations: CNN, Beth Israel Deaconess Medical Center, Harvard Medical School, University of, Mount Sinai, Novo Nordisk, Zepbound, US Centers for Disease Control, University of Pennsylvania, PCOS, Children’s Hospital, National Institutes of Health, CNN Health Locations: Steele , Alabama, Mount, United States, Children’s Hospital Colorado, —, Colorado

☆ Another perk of weight-loss drugs? Eli Lilly's Zepbound may alleviate sleep apnea, too
▼ + stars: | 2024-04-17 | by ( Hilary Brueck | ) www.businessinsider.com time to read: +4 min

GLP-1 drugs were originally developed to treat type 2 diabetes. Drugmakers are discovering the injections may also aid weight loss, heart issues, and sleep apnea. AdvertisementAnother new indication for injectable GLP-1 drugs: better sleep. On Wednesday, drugmaker Eli Lilly announced positive results from a large, phase-3 clinical trial, testing Zepbound (the drug name for tirzepatide) as a treatment for sleep apnea. Related storyAlready, GLP-1 drugs have been indicated for the treatment of:ObesityHeart diseaseAdvertisementIn clinical trials, GLP-1 drugs have also shown some promise for treating other conditions, including:Non-alcoholic fatty liver diseaseAddictionDepressionParkinson's and Alzheimer'sCancerThese breakthroughs may be tied to the gut-brain connectionScientists think that the main reason GLP-1 drugs work well is because of their effect on our body's gut-brain connection.

Persons: —, drugmaker Eli Lilly, Eli Lilly, KATERYNA, Daniel Drucker, GLP, Eric Topol Organizations: Service, Food and Drug Administration, American Diabetes Association, University of Toronto

Search resuls for: "Daniel Drucker"

4 mentions found